Health TrialsbyHealthPanel

Topotecan and Melphalan for Retinoblastoma

ConditionsRetinoblastomaChemotherapy Effect
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorSun Yat-sen University

About this trial

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

diagnosed as retinoblastoma

receiving eyeball-sparing treatment

Disqualifiers

disease progression during follow-up

Trial design

Design model

Parallel

Treatments tested in this trial

  • Topotecan

    Drug

    Topotecan intraocular injection for chemotherapy in retinoblastoma

  • Melphalan

    Drug

    Melphalan intraocular injection for chemotherapy in retinoblastoma

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: TopotecanActive comparator 1 intervention
Group B: MelphalanExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Eyeball-sparing rate

Eyeball-sparing rate during chemotherapy in retinoblastoma patients

Time frame
5 years after chemotherapy

Secondary outcomes

1

Side effects

Side effects during and after chemotherapy in retinoblastoma patients

Time frame
5 years after chemotherapy

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov
Apply now